|
|
Vaccine Detail
|
Vaccinia Virus DD-CDSR Vaccine |
| Vaccine Information |
- Vaccine Name: Vaccinia Virus DD-CDSR Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007053
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- cdsR
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: The vgf gene has been deleted by insertion of a lacZ gene into the VGF gene locus by homologous recombination and color selection after X-gal staining of plaques for a nonfunctional β-galactosidase. Homologous recombination of the cytosine deaminase and somatostain receptor genes in the TK-locus of vSC20 (vgf-deleted WR strain VV) was performed (Downs-Canner et al., 2016).
- Description: This is for various Cancer (NCT00574977). A highly tumor-selective vaccinia virus (vv) with an engineered double deletion (DD) of the thymidine kinase (tk) and vaccinia growth factor genes and additions of both a cytosine deaminase (CD) gene and a somatostatin receptor (SR) gene with potential oncolytic viral activity. The tk and vaccinia growth factor gene deletions in intratumorally administered vaccinia virus (vvDD-CDSR) help to restrict its replication and cytolytic activity to tumor cells with large nucleotide pools and tumor cells with activation of the EGFR-Ras pathway. Addition of the CD gene to the viral genome allows control of oncolytic viral infection through the administration of the prodrug 5-fluorocytosine (5-FC), converted by CD to the antimetabolite 5-fluorouracil (5-FU) in cells infected with this agent. Addition of the SR gene allows anatomical localization of vaccinia virus (vvDD-CDSR) through the use of octreotide scintigraphy (Downs-Canner et al., 2016; NCIT_C74089).
|
| Host Response |
|
|
| References |
Downs-Canner et al., 2016: Downs-Canner S, Guo ZS, Ravindranathan R, Breitbach CJ, O'Malley ME, Jones HL, Moon A, McCart JA, Shuai Y, Zeh HJ, Bartlett DL. Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers. Molecular therapy : the journal of the American Society of Gene Therapy. 2016; 24(8); 1492-1501. [PubMed: 27203445].
NCIT_C74089: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74089]
NCT00574977: [https://clinicaltrials.gov/show/NCT00574977]
|
|
